Pharmacogenomics in cancer drug discovery and development: Inhibitors of the Hsp90 molecular chaperone

Cancer Detection and Prevention

Volumn 26, Issue 6, 2002, Pages 405-410

  Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Hsp90; Molecular chaperone; Pharmacogenomics

Indexed keywords

ANTINEOPLASTIC AGENT; CHAPERONE; HEAT SHOCK PROTEIN 90;

ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG DESIGN; DRUG SCREENING; HUMAN; NEOPLASM; PHARMACOGENETICS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR CHAPERONES; NEOPLASMS; PHARMACOGENETICS;

EID: 0036919003     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(02)00126-5     Document Type: Article

References (47)

1. Garrett MD, Workman P. Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer 1999;35:2010-30.
2. Workman P. Towards genomic cancer pharmacology: Innovative drugs for the new millennium. Curr Opin Oncol, Endocrine Metab Invest Drugs 2000;2:21-4.
3. Brent R. Genomic biology. Cell 2000;100:169-83.
4. Workman P. Towards intelligent anticancer drug screening in the post genome era? Anti-Cancer Drug Design 1997;12:525-31.
5. Workman P. Scoring a bull's eye against cancer genome targets. Curr Opin Pharmacol 2001;1:342-52.
6. Workman P. Changing times: Developing cancer drugs in genomeland. Curr Opin Invest Drugs 2001;2(8):1128-35.
7. Workman P. New drug targets for genomic cancer therapy: Successes, limitations, opportunities and future challenges. Curr Cancer Drug Targets 2001;1:33-47.
8. Venter JC, et al. The sequence of the human genome. Science 2001;291:1304-51.
9. International Human Genome Sequencing Consortium: Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
10. Futreal PA, Ksprzyk A, Birney E, Mullikin JC, Wooster R, Stratton MR. Cancer and genomics. Nature 2001;409:850-5.
11. Maloney A, Workman P. Hsp90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther 2002;2:3-24.
12. Smith DF, Whitesell L, Katsanis E. Molecular chaperones: Biology and prospects for pharmacological intervention. Pharmacol Rev 1998;50:493-513.
13. Smith DF. Chaperones in signal transduction. In: Lund P, editor. Molecular Chaperones in the Cell. Oxford: Oxford University Press; 2001. p. 165-78.
14. Jolly C, Mofimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000;92:1564-72.
15. Morimoto RI. Regulation of the heat shock transcriptional response: Cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev 1998;12:3788-96.
16. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity. Invest New Drugs 1999;17:361-73.
17. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino-17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9.
18. Banerji U, O'donnell A, Scurr M, et al. Phase 1 trial of the heat shock protein 90 (Hsp90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG): Pharmacokinetic (PK) profile and pharmacodynamic (PD) endpoints. Proc Am Soc Clin Oncol 2001;20:326.
19. Tytell M, Hooper PL. Heat shock proteins: New keys to the development of cytoprotective therapies. Emerging Therapeutic Targets 2001;5:267-87.
20. Ochel HJ, Schulte TW, Nguyen P, Trepel J, Neckers L. The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase. Mol Genet Metab 1999;66:24-30.
21. de Carcer G, Avides MC, Lallena MJ, Glover DM, Gonzalez C. Requirement of Hsp90 for centrosomal function reflects its regulation of polo kinase stability. EMBO J 2001;20:2878-84.
22. Conroy SE, Latchman DS. Do heat shock proteins have a role in breast cancer? Br J Cancer 1996;74:717-21.
23. Ferranini M, Helta S, Zocchi MR, Rugarli C. Unusual expression and localization of heat shock proteins in human tumour cells. Int J Cancer 1992;16:613-9.
24. Kawanishi K, Shiozaki H, Doki Y, et al. Prognostic significance of heat shock proteins 27 and 70 in patients with squamous cell carcinoma of the esophagus. Cancer 1999;85:1649-57.
25. Jameel A, Skilton RA, Campbell TA, Chander SK, Coombes RC, Luqmani YA. Clinical and biological significance of Hsp89a in human breast cancer. Int J Cancer 1992;50:409-15.
26. Lebeau J, Le Cholony C, Prosperi MT, Goubin G. Constitutive overexpression of 89 kDa heat shock protein gene in the HBL100 mammary cell line converted to a tumorigenic phenotype by the EJ/T24 Harvey-ras oncogene. Oncogene 1991;6:1125-32.
27. Wataba K, Saito T, Fukunaka K, Nishimura M, Kudo R. Overexpression of heat shock proteins in carcinogenic endometrium. Int J Cancer 2001;91:448-56.
28. Cornford PA, Dodson AR, Parsons KF, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000;60:7099-105.
29. Martin KJ, Kritzman BM, Price LM, et al. Linking gene expression patterns to therapeutic groups in breast cancer. Cancer Res 2000;60:2232-8.
30. Whitesell L, Mimnaugh EG, De CB, Myers CE. Nechers LM. Inhibition of heat shock protein Hsp90-pp-60 v-src hetero protein complex formation by benzoquinone ansamycins; essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 2000;91:8324-8.
31. Prodromou C, Roe SM, O'brien R, Ladbury JE, Piper PW, Pearl LH. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997;90:65-75.
32. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumour agent. Cell 1997;89:339-50.
33. Roe SM, Prodromou C, O'brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumour antibiotics radicicol and geldanamycin. J Med Chem 1999;42:260-6.
34. Panaretou B, Prodromou C, Roe SM, et al. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J 1998;17:4829-36.
35. Clarke PA. Hostein I, Banerji U, et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the Hsp90 molecular chaperone. Oncogene 2000;19:4125-33.
36. Hostein I, Robertson D, Distefano F, Workman P, Clarke PA. Inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001;61:4003-9.
37. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer research. Nature 2001;411:342-8.
38. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
39. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumour agent. Cancer Chemother, Pharmacol 1995;36:305-15.
40. Brunton VG, Steele G, Lewis AD, Workman P. Geldanamycin-induced toxicity in human colon-cancer cell lines: Evidence against the involvement of c-Src or DT-diaphorase. Cancer Chemother Pharmacol 1998;41:417-22.
41. Banerji U, Walton M, Raynaud F, Kelland L, Judson I, Workman P. Validation of pharmacodynamic endpoints for the Hsp90 molecular chaperone inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG) in a human tumor xenograft model. Proc Am Assoc Cancer Res 2001;42:4473.
42. Clarke PA, Te Poele R, Wooster R, Workman P. Gene expression microarrays in cancer biology, pharmacology and drug development: Progress and potential. Biochem Pharmacol 2001;62:1211-336.
43. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamcyin binds to Hsp90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998;42:273-9.
44. Rutherford SL, Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature 1998;396:336-42.
45. Munster PN, Basso A. Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB and schedule-dependent manner. Clin Cancer Res 2001;7:2228-36.
46. Sharp S, Kelland L, Valenti M, Brunton I, Hobbs S, Workman P. Establishment of an isogenic human colon tumour model for NQO1 gene expression: Application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. Mol Pharmacol 2000;58:1146-55.
47. Aherne W, Maloney A, Promodrou C, Pearl L, Workman P, et al. Assays for Hsp90 and inhibitors. In: Adjei A, Buolamwini JK, editors. Methods in Molecular Medicine: Novel Anticancer Drug Protocols. Humana Press, in press.